4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
09 févr. 2022 08h02 HE
|
4D Molecular Therapeutics, Inc.
Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week 37 (Patient 1) and stable at 10-fold mean normal levels through week 20 (Patient 3)Preliminary...
4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium
02 févr. 2022 16h01 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
10 janv. 2022 08h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
06 janv. 2022 16h03 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for...
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
23 nov. 2021 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
10 nov. 2021 16h01 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
28 oct. 2021 21h06 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
26 oct. 2021 17h52 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
25 oct. 2021 16h03 HE
|
4D Molecular Therapeutics, Inc.
- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA...
4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
10 oct. 2021 15h50 HE
|
4D Molecular Therapeutics, Inc.
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through anatomical...